Israel-based biopharmaceutical company RedHill Biopharma recently released an update on the development of its drug pipeline, including a treatment for Crohn's disease, and announced key milestones expected by the company for the upcoming period. RedHill specializes in developing and commercializing oral, small molecule drugs to treat inflammatory and gastrointestinal diseases such as gastrointestinal cancers. RedHill is developing RHB-104 as a potential treatment for Crohn's disease, multiple sclerosis and other inflammatory diseases and is planning on completing the interim analysis of its phase III study, entitled the MAP US study, by the second half of the next year. The 26-week study includes 270 patients and has as primary endpoint of disease remission at the end of the treatment. The company is planning to enroll Crohn's patients in about 120 clinical sites in the U.S., Canada, Israel, New Zealand, Australia and Europe to participate in the phase III MAP US study. RedHill has already submitted clinical trial applications to the European authorities and may initiate the second Phase III Crohn's disease study on RHB-104, the MAP EU study, following the potential European regulatory clearance, which is expected during the third quarter of the year. In addition, the U.S. Patent and Trademark Office (USPTO) has granted the company a notice of allowance, covering the investigational treatment until at least 2029.